期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
The role of gut microbiota associated metabolites in digestive disorders
1
作者 Na Li Cheng Zhao +12 位作者 Pingnan Zhang Songting Wu Xiaotan Dou Saifei Xu Xiaoqi Zhang Chunyan Peng Ying Xie Shuling Huang Lin Zhou yonghua shen Lei Wang Jinglin Wang Chenggong Yu 《Engineered Regeneration》 EI 2024年第2期228-246,共19页
The gut has been a focal point in the research of digestive system disorders.The internal microbiota generates metabolites that function as signaling molecules and substrates,interacting with the intestinal wall and i... The gut has been a focal point in the research of digestive system disorders.The internal microbiota generates metabolites that function as signaling molecules and substrates,interacting with the intestinal wall and influ-encing host physiology and pathology.Besides,the gut microbiota and metabolites owe highly diverse types and quantities,posing challenges for quantitative analysis,and monitoring frequent interactions between diges-tive tract metabolites and the intestinal wall remains a challenge.However,research targeting gut microbiota metabolites has elucidated their relevance to digestive diseases.By modulating metabolites such as short-chain fatty acids,bile acids,and lipopolysaccharides,it is possible to intervene in the progression of diseases such as inflammatory bowel disease and non-alcoholic fatty liver disease.Currently,research on gut microbiota is advancing,and more work is required to explore the interactions between host,microbes and underlying mech-anisms.In this review,we have revisited the generation of gut microbiota-related metabolites,their impact on diseases,and modes of interaction,emphasizing the significant role of metabolites in digestive system disorders.It is believed that the linkage between gut microbiota and diseases in current research can be established through metabolites,providing a framework and foundation for research in the field of metabolomics and fundamental mechanisms. 展开更多
关键词 Gut microbial metabolites Digestive disorders Inflammatory bowel disease(IBD) Non-alcoholic fatty liver disease(NAFLD)
原文传递
超声内镜引导下肝胃吻合术治疗肝门部与远端胆道梗阻的安全性与有效性分析:一项回顾性队列研究
2
作者 颜鹏 倪牧含 +2 位作者 沈永华 孟睿 王雷 《中华消化内镜杂志》 CSCD 2023年第5期379-384,共6页
目的比较超声内镜引导下肝胃吻合术(endoscopic ultrasound-guided hepaticogastrostomy,EUS-HGS)治疗梗阻性黄疸患者不同部位胆道梗阻的安全性与有效性。方法回顾性分析2016年1月—2021年6月在南京鼓楼医院收治的82例胆道梗阻患者的临... 目的比较超声内镜引导下肝胃吻合术(endoscopic ultrasound-guided hepaticogastrostomy,EUS-HGS)治疗梗阻性黄疸患者不同部位胆道梗阻的安全性与有效性。方法回顾性分析2016年1月—2021年6月在南京鼓楼医院收治的82例胆道梗阻患者的临床资料。患者均接受EUS-HGS治疗,根据胆道梗阻位置分为肝门部胆道梗阻组(30例)和远端胆道梗阻组(52例)。使用Logistic回归进行单因素分析与多因素分析调整协变量,比较两组技术成功率、临床成功率、不良反应发生率、住院时间和费用。结果肝门部胆道梗阻组和远端胆道梗阻组的技术成功率分别为93.3%(28/30)和94.2%(49/52),两组技术成功率差异无统计学意义(P=0.870,OR=1.17,95%CI:0.18~7.41)。肝门部胆道梗阻组和远端胆道梗阻组的临床成功率分别为83.3%(25/30)和88.5%(46/52),两组临床成功率差异无统计学意义(P=0.514,OR=1.53,95%CI:0.43~5.53)。肝门部胆道梗阻术后不良反应发生率为10.0%(3/30),其中胆管炎3.3%(1/30),胆漏6.7%(2/30),胆汁性腹膜炎6.7%(2/30);而远端胆道梗阻患者不良反应发生率为17.3%(9/52),其中胆管炎9.6%(5/52),胆漏7.7%(4/52),胆汁性腹膜炎5.8%(3/52)。两组在不良事件发生率上差异均无统计学意义(P>0.05)。结论EUS-HGS治疗肝门部胆道梗阻与远端胆道梗阻的安全性和有效性均无显著差异。 展开更多
关键词 胆道 超声内镜引导下肝胃吻合术 梗阻 安全性 有效性
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部